Welcome

The Post-Finasteride Syndrome Foundation’s primary mission is to fund research on the characterization, underlying biologic mechanisms and treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS and providing support for patients suffering from the condition.

Read our FDA Citizen Petition to remove finasteride from the market.

Adverse drug reaction reports worldwide

Adverse drug reaction reports worldwide

PFS research studies published

PFS research studies published

Known suicides worldwide

Known suicides worldwide

Doctors & researchers speaking out

Doctors & researchers speaking out

Nations warning of PFS

Nations warning of PFS

National media reports worldwide

National media reports worldwide

Sources

Patient Services

Connect with other PFS patients

Consult knowledgeable doctors

Report your side effects

Read the latest research

Doctors & Researchers Speaking Out

Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use – insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.

Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020

Michael S. Irwig, MD, Attending Endocrinologist
Beth Israel Deaconess Medical Center

[A]t least 17 countries…have warned…of the potential for depression, sexual side effects, or both.

Emerging post-marketing reports of persistent depression and sexual side effects have led to growing concerns about the safety of 5α-reductase inhibitors and prompted product labeling changes in many regulatory jurisdictions. Since 2008, at least 17 countries including the United Kingdom and the United States have warned prescribers of the potential for depression, sexual side effects, or both with finasteride.

Post-Finasteride Syndrome: Efforts to explain persistent symptoms are undermined by poor long term data on harms: The BMJ, August 9, 2019

 

Shelly Gray, PharmD, Shirley & Herb Bridge Endowed Professor
University of Washington School of Pharmacy

Two subjects—eight percent—committed suicide during or after the study.

While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.

Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020

Mohit Khera, MD, Director, Laboratory for Andrology Research
Baylor College of Medicine

FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks.

Finasteride inhibits Type II 5(alpha)-reductase, which metabolizes testosterone to the potent androgen 5(alpha)-dihydrotestosterone. FDA is concerned that use of finasteride by pediatric patients may pose long-term safety risks regarding growth, development and sexual function.

FDA response to Merck & Co.’s citizen petition requesting that finasteride be added to the List of Approved Drugs for Which Additional Pediatric Information May Produce Health Benefits in the Pediatric Population: May 2000

Janet Woodcock, MD, Director of the Center for Drug Evaluation and Research
US Food and Drug Administration

Two European Documentaries a Milestone in PFS Awareness

SOMERSET, N.J., July 14, 2016 – A pair of European documentaries focusing on post-finasteride syndrome mark the first time the condition has been the subject of extended TV coverage on any continent. The first documentary, titled “Pills in Search of an Illness,” debuted April 19 on the Spanish public TV network TV3 in Barcelona. Reported […]

Finasteride-Induced Suicides up 8.4% in WHO’s VigiBase

SOMERSET, N.J., July 13, 2016 – Reports of finasteride-induced completed suicides are up 8.4% in the World Health Organization Progamme for International Drug Monitoring’s database of adverse drug reactions (ADRs) for Q1 through Q2 2016 over Q4 2015. The absolute number of completed suicides rose from 59 to 64 within that period.  Also in the […]

PFS Foundation Web Traffic Up 33% Year Over Year

SOMERSET, N.J., Jan. 5, 2016 – Traffic to the PFS Foundation website rose 33.6 percent in 2015, compared to 2014, according to Google Analytics. Concurrently, users in 161 countries—or 82.5 percent of the world (as defined by the 195 nations recognized by the U.S. Department of State)—accessed information on the condition via PFSFoundation.org in 2015, […]

Reminder: Report PFS Symptoms to National Pharmacovigilance Authorities

SOMERSET, N.J., Sept. 9, 2015 – The Post-Finasteride Syndrome Foundation is reminding PFS patients to report all persistent side effects to their respective national pharmacovigilance authorities for inclusion in the World Health Organization Progamme for International Drug Monitoring’s VigiBase database for adverse drug reactions (ADRs). Run by Uppsala Monitoring Centre (UMC), which provides scientific leadership […]